



Department of Chemistry, Lehigh University (Bethlehem, PA)

Figure 1. The classical PTPs are divided into receptor-like and non-transmembrane subfamilies [1].

- An non-transmembrane PTP about 50 kDa in size (435 amino acids).
- A negative regulator of insulin and leptin signaling pathways by dephosphorylating the phospho-tyrosine residues on the hormone receptors [2].
- PTP1B is a validated target for diabetes, obesity, and cancer [2].




Figure 2. Structure and Function of PTP1B. **A)** Structure of PTP1B with active sites C215, R221. **B)** Dephosphorylation of tyrosine residue by a phosphatase and addition by a kinase coupled with ATP.

- The PTP family is a difficult therapeutic drug target due to the highly conserved mechanism of its active sites. In addition, active site-directed ligands are highly charged and essentially cell impermeable.




Figure 3. Overview of allosteric inhibition.




Figure 4. An allosteric site located near the active site of PTP1B.

- Allosteric inhibitors of PTP's already exist, but identifying them relies on intensive compound screening and prior structural knowledge of enzyme/ligand complexes.
- **Highlights the need for a basic rational approach that can be generalized to a wide range of PTP targets.**




Figure 5. PTP1B catalyzes the dephosphorylation of p-nitrophenylphosphate to p-nitrophenol. The absorbance of p-nitrophenol can be monitored at 405nm.




Figure 6. Assay Validation. **A)** Representative calibration curve of p-nitrophenol used to determine the amount of substrate dephosphorylated during the inhibition assays. **B)** Uninhibited enzyme kinetics of PTP1B.




Figure 7. Percent Inhibition of PTP1B. 44 compounds were screened at 100 μ M using the single point enzyme inhibition assay (2 mM pNPP and 10 nM PTP1B). Compounds with positive inhibition results are shown.

Compounds with the highest percent inhibitions in the initial single point screen were tested again at 25, 50 and 100 μ M to validate their inhibition efficacy.




Figure 8. Percent Inhibition of PTP1B. Top compounds from the single point analysis were screened at the indicated concentration values in triplicates (2 mM pNPP and 10 nM PTP1B).

- Identified compounds 40 and 53 as the lead compounds for further analysis based on the results of the 2nd screen test.

- Compound 53 shows promising dose-dependence inhibition of PTP1B, but compound 40 did not exhibit a clear concentration-dependent inhibition (large error bars).




Figure 9. IC₅₀ graphs of 10 nM PTP1B with Compound (A) 53 and (B) 40 at various concentrations.




Figure 10. Chemical structures of (A) Compound 53 and (B) Compound 40.

- Test inhibitor binding affinity using thermal shift assay

- General Pipeline:




Figure 11. Pipeline diagram for identifying further novel inhibitors.

[1] Tonks, N. K. *Nat. Rev. Mol. Cell Biol.* **2006**, 7 (11), 833–846.

[2] Wiesmann, C. et al. *Nat. Struct. Mol. Biol.* **2004**, 11 (8), 730–737.